Scarica l'app Stockscreener
26.93
1.28%
-0.35
Precedente Chiudi:
$27.28
Aprire:
$27.19
Volume 24 ore:
113.38K
Relative Volume:
1.01
Capitalizzazione di mercato:
$328.21M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-24.42%
1M Prestazione:
-45.16%
6M Prestazione:
-10.53%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$26.14
$28.38
Intervallo di 1 settimana:
$26.00
$35.61
Portata 52W:
$13.59
$53.79
Q 32 Bio Inc Stock (QTTB) Company Profile
Nome
Q 32 Bio Inc
Settore
Industria
Telefono
781-999-0232
Indirizzo
830 WINTER STREET, WALTHAM
Confronta QTTB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| QTTB | 26.98 | 328.21M | 0 | 0 | 0 | 0.00 |
| VRTX | 450.61 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.05 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.59 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.41 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.82 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Q 32 Bio Inc Borsa (QTTB) Ultime notizie
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - The Malaysian Reserve
Q32 Bio Advances Clinical Trials Amidst Financial Challenges - TipRanks
Q32 Bio Inc Grapples with Internal Control Challenges Amid Compliance Costs - TipRanks
Q32 Bio: Q3 Earnings Snapshot - Milford Mirror
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update - citybiz
Q32 Bio Inc. (QTTB) Quarterly 10-Q Report - Quartzy
Q32 Bio reports Q3 EPS ($1.46), consensus ($1.40) - TipRanks
Q32 Bio to Present at Guggenheim's First Healthcare Innovation Conference | QTTB | QTTB Stock News - StockTitan
Brokerages Set Q32 Bio Inc. (NASDAQ:QTTB) Target Price at $72.33 - Defense World
Q32 Bio (NASDAQ:QTTB) Shares Down 3.6%Time to Sell? - MarketBeat
Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ - GlobeNewswire
Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ Key Companies Shaping the Future of Complement Inhibitor Therapeutics | DelveInsight - India Shorts
Q32 Bio (NASDAQ:QTTB) Stock Price Up 5% – Here’s Why - Defense World
Q32 Bio (NASDAQ:QTTB) Stock Price Up 5%Here's What Happened - MarketBeat
Raymond James Initiates Coverage of Q32 Bio (QTTB) with Strong Buy Recommendation - MSN
Q32 Bio (NASDAQ:QTTB) Research Coverage Started at Raymond James - MarketBeat
Upstream Bio stock rallies 32% following upsized $255M IPO - MSN
Oppenheimer Maintains Bullish Stance on Q32 Bio with Robust Clinical Outlook - Yahoo Finance
Oppenheimer Maintains Bullish Stance on Q32 Bio with Robust Clin - GuruFocus.com
ADX-097, potential AAV therapy, fares well in healthy volunteers - ANCA Vasculitis News
Oppenheimer holds stock target, upbeat on Q32 Bio ahead of data - Investing.com
Oppenheimer holds stock target, upbeat on Q32 Bio ahead of data By Investing.com - Investing.com South Africa
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024 - cnhinews.com
Renaissance Technologies LLC Buys 685,151 Shares of GlycoMimetics, Inc. (NASDAQ:GLYC) - Defense World
Renaissance Technologies LLC Decreases Stock Position in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Citizens Community Bancorp, Inc. (NASDAQ:CZWI) Shares Sold by Renaissance Technologies LLC - Defense World
Renaissance Technologies LLC Grows Stock Holdings in OptimumBank Holdings, Inc. (NASDAQ:OPHC) - Defense World
Renaissance Technologies LLC Acquires Shares of 66,500 Waldencast plc (NASDAQ:WALD) - Defense World
Renaissance Technologies LLC Takes $265,000 Position in Q32 Bio Inc. (NASDAQ:QTTB) - MarketBeat
Renaissance Technologies LLC Buys Shares of 84,300 Metalla Royalty & Streaming Ltd. (NYSEMKT:MTA) - Defense World
We went to a startup symposium at the University of Colorado. We saw these nine cool startups. We said "wow" a lot. - Colorado Public Radio
private equity firms who own 52% along with institutions invested in Q32 Bio Inc. (NASDAQ:QTTB) saw increase in their holdings value last week - Simply Wall St
Q32 Bio (NASDAQ:QTTB) Shares Up 4.8% – What’s Next? - Defense World
Q32 Bio (NASDAQ:QTTB) Stock Price Up 4.8%What's Next? - MarketBeat
Analysts Set Q32 Bio Inc. (NASDAQ:QTTB) PT at $68.80 - MarketBeat
Q32 Bio Inc. Patent Woes: Navigating the Perilous Waters of Intellectual Property Disputes - TipRanks
Q32 Bio's SWOT analysis: emerging biotech stock targets inflammatory diseases - Investing.com India
Q32 Bio's SWOT analysis: emerging biotech stock targets inflammatory diseases By Investing.com - Investing.com South Africa
Sherwin-Williams (SHW) Set to Announce Quarterly Earnings on Monday - Defense World
Ensign Peak Advisors Inc Purchases 38,750 Shares of Q32 Bio Inc. (NASDAQ:QTTB) - MarketBeat
Bank of New York Mellon Corp Makes New $315,000 Investment in Q32 Bio Inc. (NASDAQ:QTTB) - MarketBeat
Bruce K. Posey Sells 1,330 Shares of Qualys, Inc. (NASDAQ:QLYS) Stock - Defense World
QXO (NASDAQ:QXO) Trading Up 4.7% - MarketBeat
Q32 Bio (NASDAQ:QTTB) Trading Down 3.7% - Defense World
Q32 Bio (NASDAQ:QTTB) Shares Down 3.7% - MarketBeat
Stock Surge: Qualigen Therapeutics Inc (QLGN) Closes at 0.17, Marking a -4.84 Increase/Decrease - The Dwinnex
Q32 Bio Inc.(NasdaqGM: QTTB) added to S&P Global BMI Index - Marketscreener.com
Mutual of America Capital Management LLC Trims Stock Position in Qualys, Inc. (NASDAQ:QLYS) - Defense World
Client First Investment Management LLC Purchases New Stake in ProShares Ultra QQQ (NYSEARCA:QLD) - Defense World
Davidson Capital Management Inc. Boosts Holdings in Qualys, Inc. (NASDAQ:QLYS) - Defense World
Inspire Investing LLC Acquires 2,595 Shares of Qualys, Inc. (NASDAQ:QLYS) - Defense World
Q 32 Bio Inc Azioni (QTTB) Dati Finanziari
Non sono disponibili dati finanziari per Q 32 Bio Inc (QTTB). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Q 32 Bio Inc Azioni (QTTB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Violette Shelia M. | Chief Scientific Officer |
Oct 11 '24 |
Option Exercise |
3.12 |
4,574 |
14,271 |
17,874 |
| Violette Shelia M. | Chief Scientific Officer |
Oct 08 '24 |
Option Exercise |
3.12 |
13,300 |
41,496 |
13,300 |
| TZIANABOS ARTHUR | Director |
Mar 25 '24 |
Sale |
24.20 |
265 |
6,413 |
7,983 |
| Alloway Paul | See Remarks |
Mar 25 '24 |
Sale |
24.21 |
268 |
6,488 |
2,596 |
| Michaud Charles Jr | See Remarks |
Mar 25 '24 |
Sale |
24.20 |
75 |
1,815 |
927 |
| TZIANABOS ARTHUR | Director |
Jan 09 '24 |
Sale |
0.57 |
13,037 |
7,445 |
128,778 |
| Alloway Paul | See Remarks |
Jan 03 '24 |
Sale |
0.57 |
7,280 |
4,120 |
28,036 |
| Michaud Charles Jr | See Remarks |
Jan 03 '24 |
Sale |
0.57 |
1,708 |
975 |
11,598 |
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):